EMA: AUC72 for all IR products [General Sta­tis­tics]

posted by pmohite – India, 2020-06-24 12:08 (97 d 14:12 ago) – Posting: # 21573
Views: 1,014

Hello,

The Revised EMA Bioequivalence Guideline, Questions & Answers, Summary of the discussions held at the 3rd EGA Symposium on Bioequivalence, June 2010, London, Session 3 under question 12 states as follows:

In studies with a sampling period of 72 h, and where the concentration at 72 h is quantifiable, AUC(0-∞) and residual area do not need to be reported; it is sufficient to report AUC truncated at 72h, AUC(0-72h). A mixture of AUCt and AUC72 is acceptable as long as the sampling period allows for an adequate characterisation of AUCt. Of course, in the event samples were absent because of protocol violations on a mass scale then this would affect the acceptability of the study.


If there are around 25% of subjects missed this interval, then this will raise the acceptance of study.

Regards.


Edit: Document linked. [Helmut]

Complete thread:

Activity
 Admin contact
21,086 posts in 4,398 threads, 1,468 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time: Wednesday 02:20 CEST (Europe/Vienna)

When puzzled, it never hurts to read the primary documents 
a rather simple and self-evident principle that has, nonetheless,
completely disappeared from large sectors
of the American experience.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5